Recently, due to the revolution of immunotherapy in the treatment of nonsmall cell lung cancer (NSCLC), more drugs are being licensed to treat patients in the second-line setting. Although overall survival in these patients has been shown to increase, the same can not be said for the rate of progression-free survival. Here, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO, discusses the importance of carefully monitoring these patients during chemotherapy. This interview was recorded at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.
Progression is progression! The importance of monitoring the efficacy of immunotherapy in NSCLC
